Paclitaxel Treatment Options in United Kingdom

A collection of 293 research studies where Paclitaxel is the interventional treatment. These studies are located in the United Kingdom . Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.

Home

United Kingdom

All Treatments

Paclitaxel

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

NCT02305654

Recruiting

This is an international phase III trial, with a Bayesian design, incorporating two sequential randomisations. It efficiently examines a series of questions that routinely arise in the sequencing of treatment. The study design has evolved from lengthy international consultation that has enabled us to build consensus over which questions arise from current knowledge and practice. It will enable potential randomisation for the majority of patients with inguinal lymph node metastases and will provi... Read More

Gender:

MALE

Ages:

18 years and above

Trial Updated:

03/27/2025

Locations: Los Angeles County-USC Medical Center, Los Angeles, California +16 locations

Conditions: Squamous Cell Carcinoma of the Penis, Usual Type

Learn More ›

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

NCT04185883

Recruiting

To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

03/26/2025

Locations: Arizona Oncology Associates Professional Corporation, Tucson, Arizona +89 locations

Arizona Oncology Associates Professional Corporation, Tucson, Arizona

City of Hope National Medical Center, Duarte, California

University of California San Diego Moores Cancer Center, La Jolla, California

Loma Linda University Cancer Center, Loma Linda, California

University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California

University of California Davis Medical Center, Sacramento, California

University of California San Francisco Mission Bay Campus, San Francisco, California

University of California Los Angeles, Santa Monica, California

Rocky Mountain Cancer Centers Denver Midtown, Denver, Colorado

Sarah Cannon Research Institute, Denver, Colorado

Yale New Haven Hospital, New Haven, Connecticut

Norwalk Hospital, Norwalk, Connecticut

Memorial Cancer Institute, Pembroke Pines, Florida

Moffitt Cancer Center, Tampa, Florida

Emory University, Atlanta, Georgia

Northwestern University, Chicago, Illinois

University of Chicago, Chicago, Illinois

Indiana University, Indianapolis, Indiana

University of Iowa Hospitals and Clinics, Iowa City, Iowa

Johns Hopkins University, Baltimore, Maryland

University of Michigan, Ann Arbor, Michigan

Henry Ford Cancer Detroit (Brigitte Harris Cancer Pavilion), Detroit, Michigan

Washington University, Saint Louis, Missouri

Montefiore Medical Center, Bronx, New York

Roswell Park Cancer Institute, Buffalo, New York

Icahn School of Medicine at Mount Sinai, New York, New York

Columbia University Irving Medical Center, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Levine Cancer Institute, Charlotte, North Carolina

Duke University, Durham, North Carolina

University of Cincinnati Medical Center, Cincinnati, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Providence Portland Medical Center, Portland, Oregon

Oregon Health and Science University, Portland, Oregon

Thomas Jefferson University, Philadelphia, Pennsylvania

Fox Chase Cancer Center, Philadelphia, Pennsylvania

University of Pennsylvania, Philadelphia, Pennsylvania

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Gibbs Cancer Center and Research Institute - Spartanburg, Spartanburg, South Carolina

Avera Cancer Institute, Sioux Falls, South Dakota

United States Oncology Regulatory Affairs Corporate Office, Nashville, Tennessee

Vanderbilt University Medical Center, Nashville, Tennessee

Texas Oncology Central-South, Austin, Texas

Mary Crowley Cancer Research, Dallas, Texas

University of Texas Southwestern Medical Center, Dallas, Texas

Oncology Consultants, Houston, Texas

University of Texas MD Anderson Cancer Center, Houston, Texas

US Oncology Research Investigational Products Center, The Woodlands, Texas

Texas Oncology Northeast Texas, Tyler, Texas

Huntsman Cancer Institute, Salt Lake City, Utah

University of Virginia Cancer Center, Charlottesville, Virginia

Virginia Cancer Specialists, PC, Fairfax, Virginia

Fred Hutchinson Cancer Center, Seattle, Washington

Northwest Medical Specialties, PLLC, Tacoma, Washington

Northwest Cancer Specialists - Vancouver, Vancouver, Washington

Nepean Cancer Centre, Kingswood, New South Wales

GenesisCare -North Shore Oncology, St Leonards, New South Wales

Icon Cancer Care South Brisbane, South Brisbane, Queensland

The Queen Elizabeth Hospital, Woodville South, South Australia

St John of God Healthcare, Subiaco, Western Australia

Medizinische Universitaet Graz, Graz, Not set

Landeskrankenhaus Salzburg, Salzburg, Not set

Universite Catholique de Louvain Cliniques Universitaires Saint Luc, Bruxelles, Not set

Universitair Ziekenhuis Antwerpen, Edegem, Not set

CHU de Quebec Hopital de l Enfant Jesus, Quebec, Not set

Charite Universitaetsmedizin Berlin, Campus Virchow, Berlin, Not set

Universitaetsklinikum Dresden, Dresden, Not set

Universitaetsklinikum Essen, Essen, Not set

Universitatsklinikum Koln, Koeln, Not set

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, Not set

Azienda Ospedaliero Universitaria Pisana, Pisa, Not set

Centro Ricerche Cliniche Di Verona Societa responsabilita limitata, Verona, Not set

Aichi Cancer Center, Nagoya-shi, Aichi

National Cancer Center Hospital East, Kashiwa-shi, Chiba

The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo

Seoul National University Hospital, Seoul, Not set

The Catholic University of Korea Seoul St Marys Hospital, Seoul, Not set

Asan Medical Center, Seoul, Not set

Universitair Medisch Centrum Utrecht, Utrecht, Not set

Hospital Universitari Vall d Hebron, Barcelona, Cataluña

Hospital Clinic i Provincial de Barcelona, Barcelona, Cataluña

Institut Catala d Oncologia Hospitalet Hospital Duran i Reynals, Hospitalet de Llobregat, Cataluña

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid

Hospital Universitario Ramon y Cajal, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Taipei Veterans General Hospital, Taipei, Not set

Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan, Not set

Sarah Cannon Research Institute UK, London, Not set

Conditions: Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation

Learn More ›

Study of INCB123667 in Subjects With Advanced Solid Tumors

NCT05238922

Recruiting

This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid tumors. This study will consist of 2 parts. In Part 1, INCB123667 will be administered as monotherapy and in Part 2, INCB123667 will be administered in combination with anticancer therapies of intere... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/24/2025

Locations: City of Hope Medical Center, Duarte, California +42 locations

City of Hope Medical Center, Duarte, California

City of Hope-Lennar Foundation Cancer Center, Irvine, California

Valkyrie Clinical Trials, Los Angeles, California

Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado

Yale Cancer Center, New Haven, Connecticut

Mount Sinai Medical Center Comprehensive Cancer Center, Miami Beach, Florida

Emory University, Atlanta, Georgia

Hackensack University Medical Center, Hackensack, New Jersey

Memorial Sloan Kettering Cancer Center, New York, New York

New York Presbyterian/Weill Cornell, New York, New York

Ny Cancer and Blood Specialists, Shirley, New York

Carolina Bio-Oncology Institute, Pllc, Huntersville, North Carolina

Cleveland Clinic, Cleveland, Ohio

University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania

University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh, Pennsylvania

Allegheny Health Network, Pittsburgh, Pennsylvania

Tennessee Oncology, Nashville, Tennessee

Texas Oncology-Fort Worth South Henderson, Fort Worth, Texas

Virginia Cancer Institute, Fairfax, Virginia

University of Wisconsin, Madison, Wisconsin

Institut Bergonie, Bordeaux, Not set

Centre Leon Berard, Lyon, Not set

Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole, Toulouse, Not set

Institut Gustave Roussy, Villejuif Cedex, Not set

Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Not set

Istituto Nazionale Tumori Irccs Fondazione Pascale, Naples, Not set

Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore, Rome, Not set

Irccs Istituto Clinico Humanitas, Rozzano, Not set

Centro Ricerche Cliniche Di Verona, Verona, Not set

Aichi Cancer Center Hospital, Aichi, Not set

National Cancer Center Hospital East, Chiba, Not set

Saitama Medical University International Medical Center, Hidaka-shi, Not set

The Cancer Institute Hospital of Jfcr, Koto-ku, Not set

National Cancer Center Hospital, Tokyo, Not set

Netherlands Cancer Institute Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Not set

Erasmus Medical Center, Rotterdam, Not set

Panoncology Trials Pan American Center For Oncology Trials, Llc, Rio Piedras, Not set

Oncological Institute of Southern Switzerland, Bellinzona, Not set

Inselspital Universitatsklinik Fur Medizinische Onkologie, Bern, Not set

Centre Hospitalier Universitaire Vaudois (Chuv), Lausanne, Not set

Guys Hospital, London, Not set

Imperial College Healthcare Nhs Trust - Hammersmith Hospital, London, Not set

Northern Centre For Cancer Care, Newcastle Upon Tyne, Not set

Conditions: Solid Tumors

Learn More ›

A Study to Assess an ATX Inhibitor (IOA-289) in Patients with Metastatic Pancreatic Cancer

NCT05586516

Active Not Recruiting

The objective of study IOA-289-102 is to evaluate the safety and tolerability of escalating doses of IOA-289 in patients with metastatic pancreatic cancer in combination with standard chemotherapy consisting of gemcitabine and nab-paclitaxel. Blood and tumour samples for PK and PD will be collected and assessments for determination of any clinical efficacy will be completed.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/17/2025

Locations: Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Siena, Not set +2 locations

Conditions: Metastatic Pancreatic Cancer

Learn More ›

PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer

NCT02423603

Completed

PAKT was an investigator-led, placebo-controlled, randomized phase II trial performed in 42 academic medical centers in the United Kindom, South Korea, France, Hungary, Romania, and Georgia. Patients were randomly assigned (1:1) to receive paclitaxel plus capivasertib or paclitaxel plus placebo. Stratification was by number of metastatic sites (\< 3 v ≥ 3) and interval from the end of prior adjuvant or neoadjuvant chemotherapy (≤ 12 v \> 12 months v no prior chemotherapy). Paclitaxel was admini... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

03/07/2025

Locations: ICO René Gauducheau, Nantes, Not set +45 locations

ICO René Gauducheau, Nantes, Not set

Centre André-lacassagne, Nice, Not set

Centre Hospitalier Prive Saint-Gregoire, Saint-Grégoire, Not set

Institute of Clinical Oncology, Tbilisi, Not set

Országos Onkológiai Intézet, Budapest, Not set

University of Pécs - Clinical Center Institute of Oncotherapy, Pécs, Not set

Zala County Hospital Szent Rafael, Zalaegerszeg, Not set

Chungbuk National University Hospital, Cheongju, Not set

National Cancer Center, Goyang-si, Not set

Asan Medical Center, Seoul, Not set

Korea University Guro Hospital, Seoul, Not set

Samsung Medical Centre, Seoul, Not set

Yonsei University Health System, Seoul, Not set

Prof. Dr. I. Chiricuta Oncology Institute, Cluj-Napoca, Not set

Sf. Nectarie SRL Oncologie Medical Center, Craiova, Not set

Center of Oncology Euroclinic, Iași, Not set

Betsi Cadwaladr University Health Board, Bangor, Not set

Belfast Health and Social Care Trust, Belfast, Not set

Glan Clwyd Hospital BCU Health Board NHS Wales, Bodelwyddan, Not set

Brighton and Sussex University Hospitals NHS Trust, Brighton, Not set

Cambridge University Hospitals NHS Foundation Trust, Cambridge, Not set

East Kent Hospitals University NHS Foundation Trust, Canterbury, Not set

Velindre Cancer Centre, Cardiff, Not set

University Hospitals Coventry and Warwickshire NHs Trust, Coventry, Not set

NHS Lothian, Edinburgh, Not set

Medway NHS Foundation Trust, Gillingham, Not set

Beatson West of Scotland Cancer Centre, Glasgow, Not set

Leeds Teaching Hospitals NHs Trust, Leeds, Not set

Barts Health NHS Trust, London, Not set

University College London Hospitals, London, Not set

Barking, Havering and Redbridge University Hospitals NHS Trust, London, Not set

Guys and St Thomas' NHS Foundation Trust, London, Not set

Lewisham and Greenwich NHS Trust, London, Not set

Royal Marsden NHS Foundation Trust-Fulham, London, Not set

Imperial College Healthcare NHS Trust, London, Not set

Maidstone and Tunbridge Wells NHS Trust, Maidstone, Not set

The Christie NHS Foundation Trust, Manchester, Not set

Nottingham University Hospitals NHS Trust, Nottingham, Not set

Southampton University Hospitals NHS Trust, Southampton, Not set

Southend University Hospital NHS Foundation Trust, Southend, Not set

University Hospital of North Staffordshire NHS Trust, Stoke-on-Trent, Not set

Royal Marsden - Sutton, Sutton, Not set

Abertawe Bro Margannwg University Health Board, Swansea, Not set

Royal Cornwall Hospitals NHS Trust, Truro, Not set

Ysbyty Wrexham Maelor Hospital, Wrexham, Not set

Yeovil District Hospital NHS Foundation Trust, Yeovil, Not set

Conditions: Metastatic Breast Cancer

Learn More ›

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

NCT05743270

Withdrawn

This is a Phase 2, multicenter, open-label, 2-cohort (Locoregionally Advanced Cohort or Recurrent/Metastatic Cohort) study evaluating RP3 in combination with concurrent chemoradiation therapy (CCRT) followed by nivolumab (for the LA Cohort) or combined with chemotherapy and nivolumab (for the R/M Cohort) in patients with advanced, inoperable squamous cell carcinomas of the head and neck (SCCHN), including of the oral cavity, oropharynx, hypopharynx, larynx, or unknown primary.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/07/2025

Locations: University of California San Diego, UCSD, La Jolla, California +33 locations

University of California San Diego, UCSD, La Jolla, California

USC Norris Comprehensive Cancer Center, Los Angeles, California

UCLA Medicine Division of Hematology-Oncology, Los Angeles, California

University of Iowa Hospitals and Clinics, Iowa City, Iowa

University of Cincinnati Medical Center, Cincinnati, Ohio

Cleveland Clinic, Cleveland, Ohio

Thomas Jefferson University City Center and Abington, Philadelphia, Pennsylvania

University of Pittsburgh Medical Center, UPMC, Pittsburgh, Pennsylvania

Jefferson Health Abington Asplunhd Cancer Pavillion, Willow Grove, Pennsylvania

Sarah Cannon Research Institute, Nashville, Tennessee

University of Washington / Fred Hutchinson Cancer Center, Seattle, Washington

Medical College of Wisconsin, Milwaukee, Wisconsin

University Hospital Olomouc, Olomouc, Not set

Fakultni Thomayerova Nemocnice, Prague, Not set

FN Kralovske Vinohrady, Praha, Not set

Centre Georges Francois Leclerc, Department of Oncology, Dijon, Not set

Centre Leon Berard, Lyon, Not set

Assistance Publique Hopitaux De Marseille, Marseille, Not set

CHU Nimes, Instiut de Cancerologie du Gard, Medical Oncology, Nîmes, Not set

Institut Gustave Roussy Paris, Villejuif, Not set

Charite University Hospital of Berlin, Comprehensive Cancer Center, Berlin, Not set

Universitatsklinik Jena Klinik und Poliklinik fur Hals-, Nasen - und Ohrenheilkunde, Jena, Not set

University Hospital Leipzig Clinic and Polyclinic for otorhinolaryngology, Leipzig, Not set

LMU Klinikum, Medizinische Klinik und Poliklinikum III, Munich, Not set

Universitatsklinikum Ulm, Ulm, Not set

University General Hospital Attikon, Chaïdári, Not set

Agios Lukas Hospital, Thessaloníki, Not set

Szpital Specjalistyczny im Ludwika Rydygiera w Krakowie sp z oo, Department of Clinical Oncology, Kraków, Not set

Vall d'Hebron University Hospital, Vall d' Hebron Institute of Oncology (VHIO), Barcelona, Not set

La Paz Univeristy Hospital, Universidad Autonoma de Madrid, Madrid, Not set

Hospital Universitario HM Sanchinarro, Madrid, Not set

Clinica Universitaria de Navarra, Pamplona, Not set

Fundacion Instituto Valenciano de Oncologia, Valencia, Not set

The Royal Marsden NHS Foundation Trust, London, Not set

Conditions: Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

Learn More ›

Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC

NCT05498896

Active Not Recruiting

International, randomised, open label, neo-adjuvant phase II trial in women with newly diagnosed, non-metastatic, high-risk (node positive and/or tumour size ≥ 2cm), triple negative breast cancer. The study aims to evaluate the effects of adding ipatasertib to chemotherapy and atezolizumab in patients with and without PI3CA/AKT1/PTEN genetic alterations.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

03/07/2025

Locations: Barts Health NHS Trust, London, Not set

Conditions: Triple Negative Breast Cancer

Learn More ›

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

NCT03631784

Completed

This is a trial in adult participants with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic radiotherapy followed by pembrolizumab monotherapy. The primary hypothesis of the trial is that within each platinum doublet chemotherapy cohort, the percentage of participants who develop Grade 3 or higher pneumonitis is ≤10% and estimation of objective response rate (ORR) by bli... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/06/2025

Locations: St Joseph Heritage Healthcare ( Site 1403), Santa Rosa, California +55 locations

St Joseph Heritage Healthcare ( Site 1403), Santa Rosa, California

North Shore University Health System ( Site 1413), Evanston, Illinois

Parkview Cancer Institute ( Site 1415), Fort Wayne, Indiana

UMass Memorial Medical Center ( Site 1417), Worcester, Massachusetts

Henry Ford Hospital ( Site 1418), Detroit, Michigan

St. Francis Cancer Treatment Center ( Site 1421), Grand Island, Nebraska

Rutgers Cancer Institute of New Jersey ( Site 1422), New Brunswick, New Jersey

CTCA Southwestern ( Site 1428), Tulsa, Oklahoma

Fox Chase Cancer Center ( Site 1433), Philadelphia, Pennsylvania

Sanford Cancer Center Oncology Clinic ( Site 1434), Sioux Falls, South Dakota

Blacktown Hospital Western Sydney Local Health District ( Site 0204), Blacktown, New South Wales

MNCCI Port Macquarie Base Hospital ( Site 0200), Port Macquarie, New South Wales

Southern Medical Day Care Centre ( Site 0201), Wollongong, New South Wales

Ballarat Health Services ( Site 0206), Ballarat, Victoria

C.H. de Saint Quentin ( Site 0306), Saint Quentin, Aisne

Clinique Clairval ( Site 0311), Marseille, Bouches-du-Rhone

CHU Jean Minjoz ( Site 0301), Besancon, Doubs

Institut du Cancer de Montpellier ( Site 0300), Montpellier, Herault

C.H.R.U. de Rennes. Hopital de Pontchaillou ( Site 0302), Rennes., Ille-et-Vilaine

ICO Centre Paul Papin ( Site 0309), Angers, Maine-et-Loire

Centre Jean Perrin ( Site 0304), Clermont Ferrand, Puy-de-Dome

Clinique de L'Europe ( Site 0308), Amiens, Somme

Institut de Cancerologie Gustave Roussy ( Site 0305), Villejuif, Val-de-Marne

Thoraxklinik Heidelberg gGmbH am Universitaetsklinikum Heidelberg ( Site 0404), Heidelberg, Baden-Wurttemberg

Universitatsklinikum Mannheim GmbH ( Site 0413), Mannheim, Baden-Wurttemberg

Augusta-Kranken-Anstalt Bochum ( Site 0401), Bochum, Nordrhein-Westfalen

Bethanien Krankenhaus Moers ( Site 0406), Moers, Nordrhein-Westfalen

Klinikum Chemnitz gGmbH ( Site 0410), Chemnitz, Sachsen

LungenClinic Grosshansdorf GmbH ( Site 0408), Grosshansdorf, Schleswig-Holstein

Charite Universitaetsmedizin Berlin - Campus-Virchow-Klinikum ( Site 0414), Berlin, Not set

Katholisches Marienkrankenhaus gGmbH ( Site 0411), Hamburg, Not set

Chungbuk National University Hospital ( Site 1003), Cheongju si, Chungcheongbuk-do [Chungbuk]

National Cancer Center ( Site 1002), Goyang-si, Kyonggi-do

Samsung Medical Center ( Site 1001), Seoul, Seoul-teukbyeolsi [Seoul]

Ulsan University Hospital ( Site 1000), Ulsan, Ulsan-Kwangyokshi

Auckland City Hospital ( Site 0700), Auckland, Not set

Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 0811), Bydgoszcz, Kujawsko-pomorskie

Osrodek Badan Klinicznych przy Szpitalu Specjalistycznym ( Site 0802), Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0800), Warszawa, Mazowieckie

Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 0812), Gdynia, Pomorskie

Szpital Wojewodzki w Koszalinie im. Mikolaja Kopernika ( Site 0813), Koszalin, Zachodniopomorskie

Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 0903), Ufa, Baskortostan, Respublika

Blokhin National Medical Oncology ( Site 0902), Moscow, Moskva

National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 0904), St. Petersburg, Sankt-Peterburg

Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 0910), Kazan, Tatarstan, Respublika

Hospital Universitari Vall d Hebron ( Site 1101), Barcelona, Barcelona [Barcelona]

Hospital Clinic de Barcelona ( Site 1100), Barcelona, Barcelona [Barcelona]

Hospital Son Llatzer ( Site 1105), Palma de Mallorca, Illes Balears [Islas Baleares]

Clinica Universitaria de Navarra ( Site 1102), Madrid, Not set

Hospital Universitario Virgen Macarena ( Site 1103), Sevilla, Not set

Southampton General Hospital ( Site 1204), Southampton, Hampshire

Royal Free NHS Foundation Trust ( Site 1200), London, London, City Of

Charing Cross Hospital ( Site 1208), London, London, City Of

Beacon Centre ( Site 1203), Taunton, Somerset

Leeds Teaching Hospitals NHS Trust ( Site 1209), Leeds, Not set

Queen's Hospital ( Site 1201), Rom Valley, Not set

Conditions: Non-small Cell Lung Cancer

Learn More ›

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

NCT03798626

Completed

This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma, and the preliminary efficacy of gevokizumab in combination with the SOC anti-cancer therapy in subjects with mCRC and mGEC.

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

03/06/2025

Locations: University of California LA, Los Angeles, California +33 locations

University of California LA, Los Angeles, California

WA Uni School Of Med, Saint Louis, Missouri

Sarah Cannon Research Institute, Nashville, Tennessee

Novartis Investigative Site, Melbourne, Victoria

Novartis Investigative Site, Bruxelles, Not set

Novartis Investigative Site, Edegem, Not set

Novartis Investigative Site, Leuven, Not set

Novartis Investigative Site, Calgary, Alberta

Novartis Investigative Site, Toronto, Ontario

Novartis Investigative Site, Santiago, Not set

Novartis Investigative Site, Brno, Czech Republic

Novartis Investigative Site, Frankfurt am Main, Hessen

Novartis Investigative Site, Dresden, Not set

Novartis Investigative Site, Ulm, Not set

Novartis Investigative Site, Ramat Gan, Not set

Novartis Investigative Site, Tel Aviv, Not set

Novartis Investigative Site, Milano, MI

Novartis Investigative Site, Rozzano, MI

Novartis Investigative Site, Nagoya, Aichi

Novartis Investigative Site, Kashiwa, Chiba

Novartis Investigative Site, Osaka-city, Osaka

Novartis Investigative Site, Sunto Gun, Shizuoka

Novartis Investigative Site, Bunkyo-ku, Tokyo

Novartis Investigative Site, Seoul, Not set

Novartis Investigative Site, Singapore, Not set

Novartis Investigative Site, Sevilla, Andalucia

Novartis Investigative Site, Hospitalet de LLobregat, Catalunya

Novartis Investigative Site, Valencia, Comunidad Valenciana

Novartis Investigative Site, Madrid, Not set

Novartis Investigative Site, Tainan, Not set

Novartis Investigative Site, London, Not set

Novartis Investigative Site, Manchester, Not set

Conditions: Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma

Learn More ›

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

NCT00667251

Completed

This was a multi-center, multinational, randomized, open-label, Phase III study comparing combination taxane-based chemotherapy plus lapatinib to combination taxane-based chemotherapy plus trastuzumab in women with documented evidence of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) (by local or central laboratory testing) who had received no prior chemotherapy or HER2 targeted therapy in the metastatic setting.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

03/04/2025

Locations: Novartis Investigative Site, Anchorage, Alaska +257 locations

Novartis Investigative Site, Anchorage, Alaska

Novartis Investigative Site, Tucson, Arizona

Novartis Investigative Site, Hot Springs, Arkansas

Novartis Investigative Site, Berkeley, California

Novartis Investigative Site, Highland, California

Novartis Investigative Site, Montebello, California

Novartis Investigative Site, Colorado Springs, Colorado

Novartis Investigative Site, Denver, Colorado

Novartis Investigative Site, Greenwich, Connecticut

Novartis Investigative Site, Southington, Connecticut

Novartis Investigative Site, Stamford, Connecticut

Novartis Investigative Site, Trumbull, Connecticut

Novartis Investigative Site, Waterbury, Connecticut

Novartis Investigative Site, Kissimmee, Florida

Novartis Investigative Site, Loxahatchee Groves, Florida

Novartis Investigative Site, New Port Richey, Florida

Novartis Investigative Site, Augusta, Georgia

Novartis Investigative Site, Lawrenceville, Georgia

Novartis Investigative Site, Savannah, Georgia

Novartis Investigative Site, Post Falls, Idaho

Novartis Investigative Site, Chicago, Illinois

Novartis Investigative Site, Oak Lawn, Illinois

Novartis Investigative Site, Evansville, Indiana

Novartis Investigative Site, Goshen, Indiana

Novartis Investigative Site, Indianapolis, Indiana

Novartis Investigative Site, Munster, Indiana

Novartis Investigative Site, New Albany, Indiana

Novartis Investigative Site, Towson, Maryland

Novartis Investigative Site, Wheaton, Maryland

Novartis Investigative Site, Bozeman, Montana

Novartis Investigative Site, Grand Island, Nebraska

Novartis Investigative Site, Kearney, Nebraska

Novartis Investigative Site, Denville, New Jersey

Novartis Investigative Site, Parsippany, New Jersey

Novartis Investigative Site, Cooperstown, New York

Novartis Investigative Site, Greensboro, North Carolina

Novartis Investigative Site, Canton, Ohio

Novartis Investigative Site, Wooster, Ohio

Novartis Investigative Site, Portland, Oregon

Novartis Investigative Site, Pittsburgh, Pennsylvania

Novartis Investigative Site, Columbia, South Carolina

Novartis Investigative Site, Memphis, Tennessee

Novartis Investigative Site, Chesapeake, Virginia

Novartis Investigative Site, Salem, Virginia

Novartis Investigative Site, Bellevue, Washington

Novartis Investigative Site, Kirkland, Washington

Novartis Investigative Site, Mount Vernon, Washington

Novartis Investigative Site, Seattle, Washington

Novartis Investigative Site, Sequim, Washington

Novartis Investigative Site, Tacoma, Washington

Novartis Investigative Site, Wenatchee, Washington

Novartis Investigative Site, Milwaukee, Wisconsin

Novartis Investigative Site, Capital Federal, Buenos Aires

Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires

Novartis Investigative Site, La Plata, Buenos Aires

Novartis Investigative Site, Cipolletti, Río Negro

Novartis Investigative Site, Viedma, Río Negro

Novartis Investigative Site, Rosario, Santa Fe

Novartis Investigative Site, Santa Fe, Not set

Novartis Investigative Site, Tucuman, Not set

Novartis Investigative Site, Garran, Australian Capital Territory

Novartis Investigative Site, Liverpool, New South Wales

Novartis Investigative Site, North Sydney, New South Wales

Novartis Investigative Site, Tweed Heads, New South Wales

Novartis Investigative Site, Woolloongabba, Queensland

Novartis Investigative Site, Adelaide, South Australia

Novartis Investigative Site, Bedford Park, South Australia

Novartis Investigative Site, Kurralta Park, South Australia

Novartis Investigative Site, Hobart, Tasmania

Novartis Investigative Site, Box Hill, Victoria

Novartis Investigative Site, Fitzroy, Victoria

Novartis Investigative Site, Wodonga, Victoria

Novartis Investigative Site, Subiaco, Western Australia

Novartis Investigative Site, Gent, Not set

Novartis Investigative Site, Jette, Not set

Novartis Investigative Site, Liege, Not set

Novartis Investigative Site, Namur, Not set

Novartis Investigative Site, Edmonton, Alberta

Novartis Investigative Site, Kelowna, British Columbia

Novartis Investigative Site, Surrey, British Columbia

Novartis Investigative Site, Vancouver, British Columbia

Novartis Investigative Site, Victoria, British Columbia

Novartis Investigative Site, Winnipeg, Manitoba

Novartis Investigative Site, Moncton, New Brunswick

Novartis Investigative Site, Saint John, New Brunswick

Novartis Investigative Site, Barrie, Ontario

Novartis Investigative Site, Hamilton, Ontario

Novartis Investigative Site, Kingston, Ontario

Novartis Investigative Site, London, Ontario

Novartis Investigative Site, Newmarket, Ontario

Novartis Investigative Site, Ottawa, Ontario

Novartis Investigative Site, Sault Ste. Marie, Ontario

Novartis Investigative Site, St Catharines, Ontario

Novartis Investigative Site, Sudbury, Ontario

Novartis Investigative Site, Thunder Bay, Ontario

Novartis Investigative Site, Charlottetown, Prince Edward Island

Novartis Investigative Site, Montreal, Quebec

Novartis Investigative Site, Regina, Saskatchewan

Novartis Investigative Site, Saskatoon, Saskatchewan

Novartis Investigative Site, Quebec, Not set

Novartis Investigative Site, Angers, Not set

Novartis Investigative Site, Bordeaux, Not set

Novartis Investigative Site, Caen Cedex 05, Not set

Novartis Investigative Site, Marseille cedex 9, Not set

Novartis Investigative Site, Metz-Tessy, Not set

Novartis Investigative Site, Nantes cedex, Not set

Novartis Investigative Site, Paris, Not set

Novartis Investigative Site, Strasbourg, Not set

Novartis Investigative Site, Heidelberg, Baden-Wuerttemberg

Novartis Investigative Site, Stuttgart, Baden-Wuerttemberg

Novartis Investigative Site, Coburg, Bayern

Novartis Investigative Site, Eggenfelden, Bayern

Novartis Investigative Site, Fuerth, Bayern

Novartis Investigative Site, Regensburg, Bayern

Novartis Investigative Site, Rosenheim, Bayern

Novartis Investigative Site, Weiden, Bayern

Novartis Investigative Site, Fuerstenwalde, Brandenburg

Novartis Investigative Site, Frankfurt, Hessen

Novartis Investigative Site, Fulda, Hessen

Novartis Investigative Site, Lich, Hessen

Novartis Investigative Site, Goslar, Niedersachsen

Novartis Investigative Site, Hannover, Niedersachsen

Novartis Investigative Site, Leer, Niedersachsen

Novartis Investigative Site, Bielefeld, Nordrhein-Westfalen

Novartis Investigative Site, Bonn, Nordrhein-Westfalen

Novartis Investigative Site, Coesfeld, Nordrhein-Westfalen

Novartis Investigative Site, Essen, Nordrhein-Westfalen

Novartis Investigative Site, Koeln, Nordrhein-Westfalen

Novartis Investigative Site, Porta Westfalica, Nordrhein-Westfalen

Novartis Investigative Site, Troisdorf, Nordrhein-Westfalen

Novartis Investigative Site, Velbert, Nordrhein-Westfalen

Novartis Investigative Site, Witten, Nordrhein-Westfalen

Novartis Investigative Site, Koblenz, Rheinland-Pfalz

Novartis Investigative Site, Saarbruecken, Saarland

Novartis Investigative Site, Halle, Sachsen-Anhalt

Novartis Investigative Site, Dresden, Sachsen

Novartis Investigative Site, Luebeck, Schleswig-Holstein

Novartis Investigative Site, Berlin, Not set

Novartis Investigative Site, Brandenburg, Not set

Novartis Investigative Site, Hamburg, Not set

Novartis Investigative Site, Bangalore, Not set

Novartis Investigative Site, Nagpur, Not set

Novartis Investigative Site, Pune, Not set

Novartis Investigative Site, Beer-Sheva, Not set

Novartis Investigative Site, Holon, Not set

Novartis Investigative Site, Petah-Tikva, Not set

Novartis Investigative Site, Poriya, Not set

Novartis Investigative Site, Ramat Gan, Not set

Novartis Investigative Site, Aviano (pn), Friuli-Venezia-Giulia

Novartis Investigative Site, Roma, Lazio

Novartis Investigative Site, Sora (FR), Lazio

Novartis Investigative Site, Genova, Liguria

Novartis Investigative Site, Lecce, Puglia

Novartis Investigative Site, Sassari, Sardegna

Novartis Investigative Site, Prato (PO), Toscana

Novartis Investigative Site, Chieti, Not set

Novartis Investigative Site, Aichi, Not set

Novartis Investigative Site, Chiba, Not set

Novartis Investigative Site, Ehime, Not set

Novartis Investigative Site, Kagoshima, Not set

Novartis Investigative Site, Kanagawa, Not set

Novartis Investigative Site, Osaka, Not set

Novartis Investigative Site, Saitama, Not set

Novartis Investigative Site, Shizuoka, Not set

Novartis Investigative Site, Tokyo, Not set

Novartis Investigative Site, Gyeonggi-do, Not set

Novartis Investigative Site, Seoul, Not set

Novartis Investigative Site, Songpa-gu, Seoul, Not set

Novartis Investigative Site, Cuernavaca, Morelos

Novartis Investigative Site, Ciudad Obregon, Sonora

Novartis Investigative Site, Mexico City, Not set

Novartis Investigative Site, Amsterdam, Not set

Novartis Investigative Site, Delft, Not set

Novartis Investigative Site, Dordrecht, Not set

Novartis Investigative Site, Maastricht, Not set

Novartis Investigative Site, Gdansk, Not set

Novartis Investigative Site, Lodz, Not set

Novartis Investigative Site, Olsztyn, Not set

Novartis Investigative Site, Plock, Not set

Novartis Investigative Site, Rzeszow, Not set

Novartis Investigative Site, Warszawa, Not set

Novartis Investigative Site, Arkhangelsk, Not set

Novartis Investigative Site, Ivanovo, Not set

Novartis Investigative Site, Kazan, Not set

Novartis Investigative Site, Kirov, Not set

Novartis Investigative Site, Lipetsk, Not set

Novartis Investigative Site, Moscow, Not set

Novartis Investigative Site, Ryazan, Not set

Novartis Investigative Site, St. Petersburg, Not set

Novartis Investigative Site, Stavropol, Not set

Novartis Investigative Site, Ufa,, Not set

Novartis Investigative Site, Ufa, Not set

Novartis Investigative Site, Alcorcon, Not set

Novartis Investigative Site, Alicante, Not set

Novartis Investigative Site, Badalona, Not set

Novartis Investigative Site, Barcelona, Not set

Novartis Investigative Site, Elche, Not set

Novartis Investigative Site, Girona, Not set

Novartis Investigative Site, Jaen, Not set

Novartis Investigative Site, La Coruna, Not set

Novartis Investigative Site, Lugo, Not set

Novartis Investigative Site, Madrid, Not set

Novartis Investigative Site, Majadahonda (Madrid), Not set

Novartis Investigative Site, Pozuelo De Alarcon (Madrid), Not set

Novartis Investigative Site, Sevilla, Not set

Novartis Investigative Site, Valencia, Not set

Novartis Investigative Site, Changhua, Not set

Novartis Investigative Site, Taichung, Not set

Novartis Investigative Site, Tainan County, Not set

Novartis Investigative Site, Taipei, Not set

Novartis Investigative Site, Bangkok, Not set

Novartis Investigative Site, Chiangmai, Not set

Novartis Investigative Site, Dnepropetrovsk, Not set

Novartis Investigative Site, Dnipropetrovsk, Not set

Novartis Investigative Site, Lviv, Not set

Novartis Investigative Site, Sumy, Not set

Novartis Investigative Site, Bournemouth, Not set

Novartis Investigative Site, Brighton, Not set

Novartis Investigative Site, Chelmsford, Not set

Novartis Investigative Site, Cheltenham, Not set

Novartis Investigative Site, Colchester, Not set

Novartis Investigative Site, Cottingham, Hull, Not set

Novartis Investigative Site, Derby, Not set

Novartis Investigative Site, Edmonton, Not set

Novartis Investigative Site, Guildford, Not set

Novartis Investigative Site, Harrogate, Not set

Novartis Investigative Site, Huddersfield, Not set

Novartis Investigative Site, London, Not set

Novartis Investigative Site, Newcastle upon Tyne, Not set

Novartis Investigative Site, Norwich, Not set

Novartis Investigative Site, Nottingham, Not set

Novartis Investigative Site, Oxford, Not set

Novartis Investigative Site, Poole, Dorset, Not set

Novartis Investigative Site, Sheffield, Not set

Novartis Investigative Site, Shrewsbury, Not set

Novartis Investigative Site, Sutton, Not set

Novartis Investigative Site, Whitchurch, Cardiff, Not set

Novartis Investigative Site, York, Not set

Conditions: Breast Cancer

Learn More ›

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

NCT04623775

Active Not Recruiting

The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves overall response rate (ORR) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: Local Institution - 0160, Duarte, California +124 locations

Local Institution - 0160, Duarte, California

Local Institution - 0081, Orange, California

Local Institution - 0139, New Haven, Connecticut

Local Institution - 0153, Jacksonville, Florida

Local Institution - 0011, Port Saint Lucie, Florida

Local Institution - 0089, Athens, Georgia

Local Institution - 0121, Wichita, Kansas

Local Institution - 0159, Lexington, Kentucky

Local Institution - 0002, Louisville, Kentucky

Local Institution - 0082, Scarborough, Maine

Local Institution - 0129, Omaha, Nebraska

Local Institution - 0152, Howell, New Jersey

Local Institution - 0097, Bronx, New York

Local Institution - 0124, Johnson City, New York

Local Institution - 0162, Mineola, New York

Local Institution - 0128, New York, New York

Local Institution - 0165, New York, New York

Local Institution - 0117, Durham, North Carolina

Local Institution - 0156, Cincinnati, Ohio

Local Institution - 0155, Cleveland, Ohio

Local Institution - 0084, Lancaster, Pennsylvania

Local Institution - 0147, Pittsburgh, Pennsylvania

Local Institution - 0148, Providence, Rhode Island

Local Institution - 0083, Greenville, South Carolina

Local Institution - 0149, Dallas, Texas

Local Institution - 0091, Harlingen, Texas

Local Institution - 0001, Tyler, Texas

Local Institution - 0092, Spokane, Washington

Local Institution - 0157, Morgantown, West Virginia

Local Institution - 0037, Río Cuarto, Cordoba

Local Institution - 0021, Buenos Aires, Distrito Federal

Local Institution - 0014, Cuiudad Autonoma De Buenos Aires, Distrito Federal

Local Institution - 0039, Viedma, RIO Negro

Local Institution - 0029, Rosario, Santa Fe

Local Institution - 0060, Cordoba, Not set

Local Institution - 0038, Cordoba, Not set

Local Institution - 0073, La Rioja, Not set

Local Institution - 0055, Camperdown, New South Wales

Local Institution - 0086, Gosford, New South Wales

Local Institution - 0132, Tamworth, New South Wales

Local Institution - 0057, Adelaide, South Australia

Local Institution - 0130, Ballarat, Victoria

Local Institution - 0138, Bendigo, Victoria

Local Institution - 0141, Box Hill, Victoria

Local Institution - 0109, Frankston, Victoria

Local Institution - 0119, Murdoch, Western Australia

Local Institution - 0085, Nedlands, Western Australia

Local Institution - 0090, Graz, Not set

Local Institution - 0126, Vienna, Not set

Local Institution - 0127, Ghent, Not set

Local Institution - 0131, Ghent, Not set

Local Institution - 0125, Roeselare, Not set

Local Institution - 0063, Natal, Rio Grande Do Norte

Local Institution - 0161, Ijui, Rio Grande Do Sul

Local Institution - 0116, Porto Alegre, RIO Grande DO SUL

Local Institution - 0112, Porto Alegre, RIO Grande DO SUL

Local Institution - 0107, Barretos, Sao Paulo

Local Institution - 0111, Santo Andre, SAO Paulo

Local Institution - 0072, Rio de Janeiro, Not set

Local Institution - 0163, Sao Paulo, Not set

Local Institution - 0120, Sao Paulo, Not set

Local Institution - 0079, Santiago de Chile, Metropolitana

Local Institution - 0041, Santiago, Metropolitana

Local Institution - 0016, Santiago, Metropolitana

Local Institution - 0110, Paris, Ile De France

Local Institution - 0008, Rennes, Ille-Et-Vilaine

Local Institution - 0007, Dijon, Not set

Local Institution - 0144, Le Mans, Not set

Local Institution - 0102, Paris, Not set

Local Institution - 0035, Paris, Not set

Local Institution - 0006, Saint-Mande, Not set

Local Institution - 0065, Essen, NRW

Local Institution - 0103, Berlin, Not set

Local Institution - 0045, Berlin, Not set

Local Institution - 0062, Grosshansdorf, Not set

Local Institution - 0058, Homburg, Not set

Local Institution - 0108, Lowenstein, Not set

Local Institution - 0071, Marburg, Not set

Local Institution - 0050, Paderborn, Not set

Local Institution - 0030, Ravensburg, Not set

Local Institution - 0133, Elm Park, Dublin

Local Institution - 0023, Dublin, Not set

Local Institution - 0106, Rome, RA

Local Institution - 0028, Candiolo, Not set

Local Institution - 0009, Catania, Not set

Local Institution - 0032, Genova, Not set

Local Institution - 0059, Milano, Not set

Local Institution - 0164, Pesaro, Not set

Local Institution - 0019, Siena, Not set

Local Institution - 0070, Ciudad de Mexico, Distrito Federal

Local Institution - 0020, Toluca de Lerdo, Estado DE Mexico

Local Institution - 0115, Monterrey, Nuevo LEON

Local Institution - 0013, San Pedro Garza Garcia, Nuevo LEON

Local Institution - 0053, Harderwijk, Gelderland

Local Institution - 0158, Arnhem, Not set

Local Institution - 0145, Gdynia, Not set

Local Institution - 0036, Lublin, Not set

Local Institution - 0031, Lublin, Not set

Local Institution - 0080, Olsztyn, Not set

Local Institution - 0088, Warszawa, Not set

Local Institution - 0099, Cluj Napoca, Cluj

Local Institution - 0017, Craiova, Dolj

Local Institution - 0012, Craiova, Jud. Dolj

Local Institution - 0069, Timisoara, Timis

Local Institution - 0052, Craiova, Not set

Arkhangelsk Clinical Oncological Dispensary, Arkhangelsk, Not set

FSBI &quot,Research Institute of Influenza named after A.A. Smorodintsev &quot,of the MoH of the Rus, Saint Petersburg, Not set

LLC Eurocityclinic, Saint-Petersburg, Not set

Local Institution - 0075, Sevilla, Andalucia

Local Institution - 0137, Badalona, Barcelona

Local Institution - 0024, Barcelona, Cataluna

Local Institution - 0051, A Coruna, Not set

Local Institution - 0154, Barcelona, Not set

Local Institution - 0048, Barcelona, Not set

Local Institution - 0061, Las Palmas, Not set

Local Institution - 0074, Madrid, Not set

Local Institution - 0123, Madrid, Not set

Local Institution - 0042, Malaga, Not set

Local Institution - 0043, Valencia, Not set

Local Institution - 0015, Basel, Not set

Local Institution - 0104, St. Gallen, Not set

Local Institution - 0135, Middlesborough, Cleveland

Local Institution - 0101, London, Greater London

Local Institution - 0095, Manchester, Lancashire

Local Institution - 0067, Leicester, Not set

Conditions: Recurrent Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Non-small Cell Lung Cancer

Learn More ›

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358

Active Not Recruiting

The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally recurrent inoperable or metastatic breast cancer. The primary hypotheses are that the combination of pembrolizumab and chemotherapy is superior to placebo and chemotherapy in regards to P... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: University of Alabama at Birmingham-Medicine ( Site 0065), Birmingham, Alabama +255 locations

University of Alabama at Birmingham-Medicine ( Site 0065), Birmingham, Alabama

Arizona Oncology Associates-Arizona Oncology ( Site 0049), Tucson, Arizona

Pacific Cancer Care ( Site 0023), Monterey, California

UCSF Medical Center at Mission Bay ( Site 0043), San Francisco, California

Georgetown University Medical Center-Department of Medicine and Oncology ( Site 0026), Washington, District of Columbia

MedStar Washington Hospital Center ( Site 0063), Washington, District of Columbia

Baptist MD Anderson Cancer Center ( Site 0013), Jacksonville, Florida

Miami Cancer Institute at Baptist Health, Inc. ( Site 0070), Miami, Florida

Miami Cancer Institute - Plantation ( Site 0076), Plantation, Florida

University Cancer & Blood Center, LLC ( Site 0032), Athens, Georgia

Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0028), Marietta, Georgia

University of Illinois at Chicago ( Site 0061), Chicago, Illinois

Edward-Elmhurst Healthcare, Elmhurst Hospital-Nancy W. Knowles Cancer Center ( Site 0067), Elmhurst, Illinois

Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0066), Naperville, Illinois

Edward-Elmhurst Healthcare, Edward Hospital - Plainfield-Edward Cancer Center - Plainfield ( Site 00, Plainfield, Illinois

Orchard Healthcare Research Inc. ( Site 0037), Skokie, Illinois

Parkview Research Center at Parkview Regional Medical Center ( Site 0071), Fort Wayne, Indiana

McFarland Clinic, PC ( Site 0041), Ames, Iowa

Louisiana State University Health Sciences Shreveport ( Site 0072), Shreveport, Louisiana

CHRISTUS Highland-Oncology Research ( Site 0073), Shreveport, Louisiana

New England Cancer Specialists ( Site 0007), Scarborough, Maine

Greater Baltimore Medical Center-Medical Oncology/Hematology ( Site 0062), Baltimore, Maryland

MFSMC-HJWCI ( Site 0064), Baltimore, Maryland

MedStar Good Samaritan Hospital-Oncology Research ( Site 0069), Baltimore, Maryland

University of Massachusetts Medical School-Division of Hematology/Oncology ( Site 0052), Worcester, Massachusetts

Henry Ford Hospital ( Site 0003), Detroit, Michigan

Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0009), Omaha, Nebraska

Broome Oncology ( Site 0018), Johnson City, New York

Hematology Oncology Associates of Rockland ( Site 0044), Nyack, New York

Waverly Hematology Oncology ( Site 0015), Cary, North Carolina

Sanford Fargo Medical Center ( Site 0040), Fargo, North Dakota

Providence Portland Medical Center ( Site 0038), Portland, Oregon

Oregon Health and Science University ( Site 0031), Portland, Oregon

St Francis Cancer Center ( Site 0058), Greenville, South Carolina

Sanford Cancer Center ( Site 0021), Sioux Falls, South Dakota

University of Tennessee Medical Center ( Site 0039), Knoxville, Tennessee

Bon Secours St. Francis Medical Center-Oncology Research ( Site 0020), Midlothian, Virginia

Kadlec Clinic Hematology and Oncology ( Site 0055), Kennewick, Washington

Medical Oncology Associates, PS ( Site 0010), Spokane, Washington

Northwest Medical Specialties, PLLC ( Site 0008), Tacoma, Washington

North Star Lodge ( Site 0035), Yakima, Washington

Centro de Oncología e Investigación de Buenos Aires ( Site 0400), Berazategui, Buenos Aires

Hospital Británico de Buenos Aires-Oncology ( Site 0404), Ciudad autónoma de Buenos Aires, Buenos Aires

Instituto de Investigaciones Clínicas Mar del Plata ( Site 0412), Mar del Plata, Buenos Aires

Hospital Aleman-Oncology ( Site 0402), Buenos Aires, Caba

Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0403), Buenos Aires, Caba

Sanatorio de La Mujer ( Site 0405), Rosario, Santa Fe

Sanatorio Parque ( Site 0407), Rosario, Santa Fe

Instituto de Oncología de Rosario ( Site 0401), Rosario, Santa Fe

Hospital Italiano de Córdoba ( Site 0409), Cordoba, Not set

Fundación CEMAIC ( Site 0410), Cordoba, Not set

Instituto San Marcos ( Site 0408), San Juan, Not set

Macquarie University-MQ Health Clinical Trials Unit ( Site 2102), Macquarie Park, New South Wales

Westmead Hospital-Department of Medical Oncology ( Site 2101), Westmead, New South Wales

Frankston Hospital-Oncology and Haematology ( Site 2103), Frankston, Victoria

Breast Cancer Research Centre-WA ( Site 2104), Nedlands, Western Australia

Landesklinikum Wiener Neustadt-Innere Medizin, Hämatologie und internistische Onkologie ( Site 1604), Wiener Neustadt, Niederosterreich

Medizinische Universität Graz-Innere Medizin Klin. Abt. Onkologie ( Site 1609), Graz, Steiermark

Medizinische Universitaet Innsbruck ( Site 1602), Innsbruck, Tirol

Medizinische Universität Wien ( Site 1601), Vienna, Wien

Uniklinikum Salzburg-Universitätsklinik für Innere Medizin III der PMU mit Hämatologie, internistis, Salzburg, Not set

Hospital de Câncer de Recife ( Site 0211), Recife, Pernambuco

Instituto de Oncologia Saint Gallen ( Site 0206), Santa Cruz do Sul, Rio Grande Do Sul

Clínica de Oncologia Reichow ( Site 0210), Blumenau, Santa Catarina

YNOVA Pesquisa Clínica ( Site 0203), Florianópolis, Santa Catarina

Instituto Nacional de Câncer - INCA-Pesquisa Clinica HC3 ( Site 0208), Rio de Janeiro, Not set

Instituto de Educação, Pesquisa e Gestão em Saúde ( Site 0202), Rio de Janeiro, Not set

Tom Baker Cancer Center ( Site 0107), Calgary, Alberta

North York General Hospital ( Site 0108), Toronto, Ontario

Princess Margaret Cancer Centre ( Site 0101), Toronto, Ontario

Jewish General Hospital ( Site 0110), Montreal, Quebec

Centre Hospitalier de l'Université de Montréal ( Site 0105), Montréal, Quebec

Hopital Du Saint-Sacrement ( Site 0109), Quebec City, Quebec

Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec (, Trois-Rivières, Quebec

Centro Investigación del Cáncer James Lind ( Site 0513), Temuco, Araucania

FALP ( Site 0501), Santiago, Region M. De Santiago

Oncovida ( Site 0514), Santiago, Region M. De Santiago

Clínica RedSalud Vitacura ( Site 0515), Santiago, Region M. De Santiago

Instituto Nacional del Cancer-CR Investigación ( Site 0511), Santiago, Region M. De Santiago

Bradfordhill ( Site 0500), Santiago, Region M. De Santiago

Anhui Cancer Hospital-medical oncology ( Site 2632), Hefei, Anhui

Cancer Hospital Chinese Academy of Medical Science ( Site 2635), Beijing, Beijing

Beijing Cancer hospital-Department of Breast Cancer ( Site 2605), Beijing, Beijing

Beijing Peking Union Medical College Hospital-Medical Oncology ( Site 2610), Beijing, Beijing

The First Affiliated hospital of Xiamen University-Breast Surgery ( Site 2613), Xiamen, Fujian

The First People's Hospital of Foshan-Oncology Department of Breast Cancer ( Site 2620), Foshan, Guangdong

SUN YAT-SEN UNIVERSITY CANCER CENTRE-oncology breast ( Site 2616), Guangzhou, Guangdong

Sun Yat-sen Memorial Hospital, Sun Yat-sen University-Breast Oncology Center ( Site 2641), Guangzhou, Guangdong

Peking University Shenzhen Hospital-Oncology Department ( Site 2601), Shenzhen, Guangdong

Guangxi Medical University Affiliated Tumor Hospital-Oncology Dept. of Breast and Bone Soft Tissue (, Nanning, Guangxi

Henan Cancer Hospital-Galactophore Department ( Site 2615), Zhengzhou, Henan

Wuhan Union Hospital Cancer Center-Cancer Center ( Site 2629), Wuhan, Hubei

Xiangya Hospital Central South University-Breast department ( Site 2621), Changsha, Hunan

Hunan Cancer Hospital ( Site 2608), Changsha, Hunan

Jiangsu provincial people's hospital-Oncology Department ( Site 2607), Nanjing, Jiangsu

The Third Hospital of Nanchang-Oncology Dept ( Site 2628), Nanchang, Jiangxi

Jilin Cancer Hospital-oncology department ( Site 2619), Changchun, Jilin

The First Affiliated Hospital of Xian Jiaotong University wa-Oncology ( Site 2604), Xi'an, Shaanxi

Shandong Cancer Hospital-Breast surgery ( Site 2623), Jinan, Shandong

Fudan University Shanghai Cancer Center-Oncology ( Site 2600), Shanghai, Shanghai

Renji Hospital Shanghai Jiao Tong University School of Medicine-Breast surgery ( Site 2626), Shanghai, Shanghai

West China Hospital Sichuan University-Head and Neck Oncology ( Site 2630), Cheng Du, Sichuan

Tianjin Medical University Cancer Institute and Hospital-Department of Breast Cancer ( Site 2612), Tianjin, Tianjin

Xinjiang Medical University Cancer Hospital - Urumqi-galactophore department ( Site 2624), Urumqi, Xinjiang

Zhejiang Cancer Hospital-Breast Oncology ( Site 2622), Hangzhou, Zhejiang

Taizhou Hospital of Zhejiang Province ( Site 2636), Linhai, Zhejiang

The First Affiliated Hospital of Wenzhou Medical University-Thyroid and breast surgery ( Site 2625), Wenzhou, Zhejiang

Fundación Colombiana de Cancerología Clínica Vida ( Site 0605), Medellín, Antioquia

Instituto de Cancerología-Oncology ( Site 0606), Medellín, Antioquia

Clinica de la Costa S.A.S. ( Site 0601), Barranquilla, Atlantico

Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 0603), Valledupar, Cesar

Oncomedica S.A.-Oncomedica S.A ( Site 0604), Montería, Cordoba

Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 0607), Bogota, Distrito Capital De Bogota

Institut Paoli-Calmettes ( Site 0913), Marseille, Bouches-du-Rhone

Centre François Baclesse ( Site 0920), Caen, Calvados

CHU Besançon ( Site 0918), Besançon, Franche-Comte

Institut Claudius Regaud ( Site 0902), Toulouse, Haute-Garonne

Gustave Roussy ( Site 0914), Villejuif, Ile-de-France

Centre de Cancérologie du Grand Montpellier ( Site 0912), Montpellier, Languedoc-Roussillon

Institut de Cancérologie de l'Ouest ( Site 0907), Saint Herblain, Loire-Atlantique

Institut de Cancérologie de l'Ouest ( Site 0915), ANGERS cedex 02, Maine-et-Loire

Centre Oscar Lambret ( Site 0921), Lille, Nord

Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne ( Site 0901), Clermont-Ferrand, Puy-de-Dome

CENTRE LEON BERARD ( Site 0919), Lyon, Rhone-Alpes

Centre de Lutte Contre le Cancer - Centre Henri Becquerel Normandie Rouen ( Site 0904), Rouen, Seine-Maritime

Centre Hospitalier Universitaire de Poitiers-Pôle régional de cancérologie ( Site 0922), Poitiers, Vienne

Institut Curie ( Site 0900), Paris, Not set

Universitaetsklinikum Erlangen-Klinik für Gynäkologie und Geburtshilfe ( Site 1202), Erlangen, Bayern

Gynaekologisches Zentrum Bonn ( Site 1201), Bonn, Nordrhein-Westfalen

Universitaetsklinikum Duesseldorf-Klinik für Frauenheilkunde & Geburtshilfe ( Site 1204), Düsseldorf, Nordrhein-Westfalen

Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung-Klinike für Senologie/ Brustzentrum ( Site 1200, Essen, Nordrhein-Westfalen

Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Frauenheilkunde und Gebur, Dresden, Sachsen

Vivantes Klinikum Am Urban-Haematologie und Onkologie ( Site 1203), Berlin, Not set

General Hospital of Athens Laiko-First Department of Internal Medicine ( Site 0305), Athens, Attiki

Alexandra Hospital-ONCOLGOY DEPT. ( Site 0302), Athens, Attiki

Hygeia Hospital-3rd Oncology Department ( Site 0304), Marousi, Attiki

University General Hospital of Heraklion-Internal Medicine-Oncology ( Site 0303), Heraklion, Irakleio

Euromedica General Clinic Thessaloniki-Oncology Unit ( Site 0301), Thessaloniki, Not set

CELAN,S.A ( Site 0151), Guatemala, Not set

Gastrosoluciones ( Site 0156), Guatemala, Not set

INTEGRA Cancer Institute ( Site 0155), Guatemala, Not set

Centro Medico Integral De Cancerología (CEMIC) ( Site 0154), Quetzaltenango, Not set

Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 2804), Kecskemét, Bacs-Kiskun

Pécsi Tudományegyetem Klinikai Központ-Onkoterápiás Intézet ( Site 2807), Pécs, Baranya

Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Onkoterapias Klinika ( Site 2805), Szeged, Csongrad

St. James's Hospital ( Site 1530), Dublin, Not set

St. Vincent's University Hospital-Medical Oncology Research Department ( Site 1531), Dublin, Not set

Assuta Ashdod Medical Center ( Site 1703), Ashdod, Not set

Soroka Medical Center-Oncology ( Site 1702), Be'er Sheva, Not set

Bnai Zion Medical Center-Oncology ( Site 1704), Haifa, Not set

Sheba Medical Center-ONCOLOGY ( Site 1700), Ramat Gan, Not set

Sourasky Medical Center-Oncology ( Site 1701), Tel Aviv, Not set

Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1113), Roma, Lazio

Ospedale San Raffaele-Oncologia Medica ( Site 1110), Milano, Lombardia

Ospedale San Gerardo-ASST Monza-Research Unit Phase 1 ( Site 1115), Monza, Lombardia

Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1114), Rozzano, Milano

Instituto Tumori Giovanni Paolo II-ONCOLOGIA MEDICA ( Site 1112), Bari, Not set

Ospedale Cannizzaro ( Site 1118), Catania, Not set

Istituto Europeo di Oncologia IRCCS-Divisione di Senologia Medica ( Site 1111), Milano, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1116), Napoli, Not set

Istituto Oncologico Veneto IRCCS ( Site 1117), Padova, Not set

Hyogo Medical University Hospital ( Site 2201), Nishinomiya, Hyogo

St. Marianna University School of Medicine Hospital ( Site 2205), Kawasaki, Kanagawa

Kitasato University Hospital ( Site 2204), Sagamihara, Kanagawa

Osaka University Hospital ( Site 2211), Suita, Osaka

Saitama Medical University International Medical Center ( Site 2208), Hidaka-city, Saitama

Tokyo Medical University Hospital ( Site 2206), Shinjuku-ku, Tokyo

Chiba University Hospital ( Site 2212), Chiba, Not set

National Hospital Organization Kyushu Cancer Center ( Site 2209), Fukuoka, Not set

Fukushima Medical University ( Site 2200), Fukushima, Not set

Kumamoto University ( Site 2203), Kumamoto, Not set

St. Luke's International Hospital ( Site 2207), Tokyo, Not set

Juntendo University Hospital ( Site 2210), Tokyo, Not set

National Cancer Center-Center for Breast Cancer ( Site 2404), Goyang-si, Kyonggi-do

Seoul National University Bundang Hospital ( Site 2406), Seongnam, Kyonggi-do

Seoul National University Hospital-Internal Medicine ( Site 2403), Seoul, Not set

Severance Hospital, Yonsei University Health System ( Site 2400), Seoul, Not set

Asan Medical Center ( Site 2402), Seoul, Not set

Samsung Medical Center-Division of Hematology/Oncology ( Site 2401), Seoul, Not set

University Malaya Medical Centre ( Site 2505), Lembah Pantai, Kuala Lumpur

Hospital Pulau Pinang ( Site 2504), George Town, Pulau Pinang

Sarawak General Hospital-Radiotherapy Unit ( Site 2501), Kuching, Sarawak

Hospital Kuala Lumpur-Radiotherapy and Oncology ( Site 2506), Kuala Lumpur, Not set

Pantai Hospital Kuala Lumpur-Cancer Centre ( Site 2503), Kuala Lumpur, Not set

Samadhi Centro Oncológico ( Site 0258), México, Distrito Federal

Hospital Civil Fray Antonio Alcalde-Oncology ( Site 0262), Guadalajara, Jalisco

Filios Alta Medicina ( Site 0253), Monterrey, Nuevo Leon

Centro Estatal de Cancerologia-Investigación ( Site 0256), Chihuahua, Not set

Centro de Investigacion Clinica de Oaxaca ( Site 0252), Oaxaca, Not set

Radboudumc-Medical Oncology ( Site 1360), Nijmegen, Gelderland

Maastricht UMC+-Medical Oncology ( Site 1353), Maastricht, Limburg

Jeroen Bosch Hospital ( Site 1359), Den Bosch, Noord-Brabant

Elisabeth-TweeSteden Ziekenhuis-Internal Medicine ( Site 1357), Tilburg, Noord-Brabant

Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL) ( Site 1351), Amsterdam, Noord-Holland

Meander Medisch Centrum ( Site 1358), Amersfoort, Utrecht

Leids Universitair Medisch Centrum-Medical Oncology ( Site 1356), Leiden, Zuid-Holland

Haaglanden MC - locatie Antoniushove-Medical oncology ( Site 1355), Leidschendam, Zuid-Holland

Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1354), Schiedam, Zuid-Holland

East Avenue Medical Center ( Site 0802), Quezon City, National Capital Region

CARDINAL SANTOS MEDICAL CENTER-Research Room ( Site 0800), San Juan, National Capital Region

Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1813), Bydgoszcz, Kujawsko-pomorskie

Pratia MCM Krakow ( Site 1809), Krakow, Malopolskie

Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1818), Siedlce, Mazowieckie

Lux med onkologia sp. z o.o. ( Site 1808), Warsaw, Mazowieckie

Luxmed Onkologia sp. z o. o. ( Site 1820), Warszawa, Mazowieckie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Piersi i Chirurgii (, Warszawa, Mazowieckie

Wojskowy Instytut Medyczny-Klinika Onkologii ( Site 1803), Warszawa, Mazowieckie

Mazowiecki Szpital Onkologiczny-BREAST CANCER ( Site 1821), Wieliszew, Mazowieckie

Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1819), Przemysl, Podkarpackie

Bialostockie Centrum Onkologii-Oddzial Onkologii Klinicznej ( Site 1812), Bialystok, Podlaskie

Narodowy Instytut Onkologii - Oddzial w Gliwicach-Breast Unit ( Site 1811), Gliwice, Slaskie

Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1815), Koszalin, Zachodniopomorskie

Champalimaud Foundation ( Site 1006), Lisbon, Lisboa

Centro Hospitalar Universitário Lisboa Norte, E.P.E. - Hospital de Santa Maria ( Site 1004), Lisbon, Lisboa

UNIDADE LOCAL DE SAUDE DE MATOSINHOS ( Site 1007), Matosinhos, Porto

Centro Hospitalar do Porto - Hospital de Santo António-Oncology Service ( Site 1003), Porto, Not set

Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 1005), Porto, Not set

Cardiomed SRL Cluj-Napoca ( Site 2902), Cluj-Napoca, Cluj

Institutul Oncologic-Day Hospital Unit ( Site 2905), Cluj-Napoca, Cluj

Centrul de Oncologie "Sfântul Nectarie"-Medical Oncology ( Site 2901), Craiova, Dolj

Oncopremium Team-Oncology ( Site 2903), Baia Mare, Maramures

Sigmedical Services SRL ( Site 2904), Suceava, Not set

Arkhangelsk Clinical Oncological Dispensary-Chemotherapy department ( Site 1902), Arkhangelsk, Arkhangel Skaya Oblast

Podolsk Regional Clinical Hospital ( Site 1907), Podolsk, Moskovskaya Oblast

Moscow Clinical Research Center-Chemotherapy department ( Site 1903), Moscow, Moskva

Fed State Budgetary Inst N.N. Blokhin Med Center of Oncology MHRF ( Site 1901), Moscow, Moskva

Central Clinical Hospital of the Presidential Administrative Department ( Site 1904), Moscow, Moskva

Nizhegorodsky Regional Oncology Dispensary-chemotherapy ( Site 1912), Nizhniy Novgorod, Nizhegorodskaya Oblast

Ryazan Regional Clinical Oncology Center-Oncology #1 ( Site 1906), Ryazan, Ryazanskaya Oblast

N.N.Petrov Research Institute of Oncology ( Site 1900), Saint Petersburg, Sankt-Peterburg

St. Petersburg Clinical Hospital of Russian Academy Of Sciences-Medical Oncology ( Site 1905), St. Petersburg, Sankt-Peterburg

Hospital Quiron Barcelona ( Site 1326), Barcelona, Cataluna

HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 1333), Madrid, Madrid, Comunidad De

Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1320), Madrid, Madrid, Comunidad De

HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1323), Pozuelo de Alarcon, Madrid

Fundación Instituto Valenciano de Oncología-Oncologico ( Site 1332), Valencia, Valenciana, Comunitat

Karolinska Universitetssjukhuset Solna-Tema Cancer - ME Bröst- endokrina tumörer och sarkom ( Site 1, Stockholm, Stockholms Lan

Södra Älvsborg Sjukhus ( Site 1406), Borås, Vastra Gotalands Lan

Ege University Medicine of Faculty ( Site 2004), Bornova, Izmir

I.E.U. Medical Point Hastanesi-Oncology ( Site 2016), Izmir, Karsiyaka, Izmir

Baskent University Dr. Turgut Noyan Research and Training Center ( Site 2013), Adana, Not set

Hacettepe Universitesi-oncology hospital ( Site 2000), Ankara, Not set

Memorial Ankara Hastanesi-Medical Oncology ( Site 2002), Ankara, Not set

Gazi Universitesi-Oncology ( Site 2010), Ankara, Not set

ANKARA ŞEHİR HASTANESİ-Medical Oncology ( Site 2014), Ankara, Not set

Akdeniz Universitesi Hastanesi-Medical Oncology ( Site 2009), Antalya, Not set

Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 2012), Istanbul, Not set

TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2005), Istanbul, Not set

İnönü Üniversitesi Turgut Özal Tıp Merkezi Eğitim ve Araştırma Hastanesi-Medical Oncology Department, Malatya, Not set

The Royal Cornwall Hospital ( Site 1507), Truro, Cornwall

Leicester Royal Infirmary-HOPE Clinical Trials Unit ( Site 1502), Leicester, England

St Bartholomew's Hospital ( Site 1508), London, England

The Christie ( Site 1510), Manchester, England

Blackpool Victoria Hospital ( Site 1503), Blackpool, Lancashire

North West Cancer Centre ( Site 1511), Londonderry, London, City Of

Guy's & St Thomas' NHS Foundation Trust ( Site 1501), London, London, City Of

Conditions: Breast Neoplasms

Learn More ›